Antibodies News and Research

RSS

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.

21 Apr 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms

Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.

20 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Limited SARS-CoV-2 spread in childcare centers, finds study

A new study adds to the sum of evidence that children do not play a key role in the transmission of the SARS-CoV-2, the pathogen behind the current pandemic of COVID-19.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

New research has been published in The Lancet Respiratory Medicine, which focuses on evaluating the effect of SARS-CoV-2 seropositivity on the possibility of developing SARS-CoV-2 infection in a young and healthy population. This study is based on the longitudinal prospective cohort study that involves the COVID-19 Health Action Response for Marines (CHARM).

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

New mathematical model could help design new probiotics and tailored diets to prevent diseases

A new mathematical model for the interaction of bacteria in the gut could help design new probiotics and specially tailored diets to prevent diseases. The research, from Chalmers University of Technology in Sweden, was recently published in the journal PNAS.

20 Apr 2021

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Opioid addicts wage a daily war within over whether or not to use a drug whose side effect can be death. If those same addicts, however, had the choice to take an opioid vaccine once or twice a year, their internal struggle could be over.

20 Apr 2021

Immune tolerance in hemophilia can be modulated by B cell activating factor

A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Antibodies may not inhibit SARS-COV-2 variants from mink

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals.

19 Apr 2021

Antibodies News and Research

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Limited SARS-CoV-2 spread in childcare centers, finds study

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

New mathematical model could help design new probiotics and tailored diets to prevent diseases

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Immune tolerance in hemophilia can be modulated by B cell activating factor

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers manufacture the SARS-CoV-2 RBD in pichia

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Antibodies may not inhibit SARS-COV-2 variants from mink

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo